Inhibition of gastric acid secretion by cimetidine in patients with duodenal ulcer
- PMID: 239346
- DOI: 10.1056/NEJM197508212930802
Inhibition of gastric acid secretion by cimetidine in patients with duodenal ulcer
Abstract
Cimetidine, a non-thiourea-containing H2-receptor antagonist, was studied in seven patients with duodenal ulcer. Oral doses of 100, 200, and 300 mg were tested. Each dose significantly inhibited basal and meal-stimulated secretion. After 300 mg, basal acid secretion was essentially zero for at least five hours. The meal-stimulated three-hour acid output after the 300-mg dose was reduced by 67%. Cimetidine, 300 mg, decreased meal-stimulated acid secretion significantly more than an optimal effective dose of propantheline bromide (P less than 0.05). Inhibition of meal-stimualted gastric acid secretion showed a significant relation to peak blood cimetidine concentration (r is equal to 0.76, P less than 0.01). Cimetidine did not affect meal-stimulated gastrin release. No toxicity was observed after serial doses given during these tests. Cimetidine may be useful in treatment of acid-peptic diseases provided no important toxicity appears on chronic testing.
Similar articles
-
The effect of cimetidine, a new histamine H2-receptor antagonist, on meal-stimulated acid secretion, serum gastrin, and gastric emptying in patients with duodenal ulcer.Gastroenterology. 1976 Jul;71(1):19-23. Gastroenterology. 1976. PMID: 6359 Clinical Trial.
-
Cimetidine suppression of nocturnal gastric secretion in active duodenal ulcer.N Engl J Med. 1976 Apr 8;294(15):801-4. doi: 10.1056/NEJM197604082941502. N Engl J Med. 1976. PMID: 2870 Clinical Trial.
-
Metiamide, an H2-receptor blocker, as inhibitor of basal and meal-stimulated gastric acid secretion in patients with duodenal ulcer.N Engl J Med. 1974 Aug 22;291(8):373-6. doi: 10.1056/NEJM197408222910801. N Engl J Med. 1974. PMID: 4152590 Clinical Trial. No abstract available.
-
Cholecystokinin in the control of gastric acid and plasma gastrin and somatostatin secretion in healthy subjects and duodenal ulcer patients before and after eradication of Helicobacter pylori.J Physiol Pharmacol. 1994 Dec;45(4 Suppl 1):3-66. J Physiol Pharmacol. 1994. PMID: 7787215 Review.
-
Cimetidine: a review of its pharmacological properties and therapeutic efficacy in peptic ulcer disease.Drugs. 1978 Feb;15(2):93-131. doi: 10.2165/00003495-197815020-00002. Drugs. 1978. PMID: 342231 Review.
Cited by
-
Malabsorption of protein-bound cobalamin but not unbound cobalamin during cimetidine administration.Dig Dis Sci. 1980 Mar;25(3):188-91. doi: 10.1007/BF01308137. Dig Dis Sci. 1980. PMID: 6768534
-
Relationship between asthma and gastro-oesophageal reflux.Thorax. 1981 Feb;36(2):116-21. doi: 10.1136/thx.36.2.116. Thorax. 1981. PMID: 7022737 Free PMC article. Clinical Trial.
-
Randomized prospective evaluation of cimetidine and antacid control of gastric pH in the critically ill.Ann Surg. 1980 Aug;192(2):169-74. doi: 10.1097/00000658-198008000-00006. Ann Surg. 1980. PMID: 7406571 Free PMC article. Clinical Trial.
-
Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.Clin Pharmacokinet. 1991 Mar;20(3):218-36. doi: 10.2165/00003088-199120030-00004. Clin Pharmacokinet. 1991. PMID: 1673880 Review.
-
Reduction of endoscopically assessed acute aspirin-induced gastric mucosal injury with cimetidine.Dig Dis Sci. 1987 Aug;32(8):851-6. doi: 10.1007/BF01296708. Dig Dis Sci. 1987. PMID: 3301232 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources